340B Dispute Resolution Decisions Subject To Administrative Appeal Under Proposal
Executive Summary
US Health and Human Services Department revises approach to 340B administrative dispute resolution process and presiding panel in proposed rule.
You may also be interested in...
340B Audit ‘Protections’ Needed Prior To Dispute Resolution Final Rule, Lilly Tells OMB
Lilly wants White House Office of Management and Budget to delay final rule until there are regulatory controls against duplicate and diverted discounts. OMB has also held three meetings over past few months with organizations representing 340B providers.
340B Contract Pharmacy Restrictions Slowed Program’s 2021 Spending Trajectory, But Not Much
Manufacturer restrictions on discounts to contract pharmacies may have depressed sales for 340B-discounted diabetes drugs in 2021. But sales in other categories, including oncology, immunology and arthritis drugs, were up by 20% to 40%.
Supreme Court Rules Narrowly Against Medicare Payments Cuts To 340B Hospitals
The decision doesn’t directly impact manufacturers or the 340B discounts they are required to provide – and does not address the potentially much broader regulatory issue of whether the Supreme Court’s so-called Chevron doctrine should be changed.